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Abstract
Background: Some breast cancer patients receiving anti-angiogenic treatment show increased metastases, possibly
as a result of induced hypoxia. The effect of hypoxia on tumor cell migration was assessed in selected luminal,
post-EMT and basal-like breast carcinoma cell lines.
Methods: Migration was assessed in luminal (MCF-7), post-EMT (MDA-MB-231, MDA-MB-435S), and basal-like (MDA-
MB-468) human breast carcinoma cell lines under normal and oxygen-deprived conditions, using a collagen-based
assay. Cell proliferation was determined, secreted cytokine and chemokine levels were measured using flow-
cytometry and a bead-based immunoassay, and the hypoxic genes HIF-1a and CA IX were assessed using PCR.
The functional effect of tumor-cell conditioned medium on the migration of neutrophil granulocytes (NG) was
tested.
Results: Hypoxia caused increased migratory activity but not proliferation in all tumor cell lines, involving the
release and autocrine action of soluble mediators. Conditioned medium (CM) from hypoxic cells induced migration
in normoxic cells. Hypoxia changed the profile of released inflammatory mediators according to cell type.
Interleukin-8 was produced only by post-EMT and basal-like cell lines, regardless of hypoxia. MCP-1 was produced
by MDA-MB-435 and -468 cells, whereas IL-6 was present only in MDA-MB-231. IL-2, TNF-a, and NGF production
was stimulated by hypoxia in MCF-7 cells. CM from normoxic and hypoxic MDA-MB-231 and MDA-MB-435S cells
and hypoxic MCF-7 cells, but not MDA-MB-468, induced NG migration.
Conclusions: Hypoxia increases migration by the autocrine action of released signal substances in selected luminal
and basal-like breast carcinoma cell lines which might explain why anti-angiogenic treatment can worsen clinical
outcome in some patients.
Background
One of the hallmarks of cancer is the replicative poten-
tial of tumor cells [1]. However, fast growing tumors
need to be supplied with nutrients and oxygen which
cannot be sufficiently sustained by diffusion alone and
so requires sustained angiogenesis [1]. Without angio-
genesis, oxygen deprivation occurs, and to evade this
fate, hypoxic tumor cells release cell signalling sub-
stances that induce angiogenesis [2], regulated by
hypoxia-inducible factor (HIF) which is a key element in
the hypoxic pathway [3]. Therapeutic anti-angiogenic
strategies have been established to limit tumour growth
[4] and because of its pivotal role HIF-1a is especially
targeted for such treatment [5]. HIF-1a over-expression
and signalling are reported to correlate with poor prog-
nosis and high metastasis formation [6,7]. Paradoxically,
therapeutic anti-angiogenic or angiostatic strategies have
been proposed to increase in metastasis formation [6,8].
Basal-like breast cancers differ to luminal cancers in
being triple negative for the immunophenotypic markers
ER
-/PGR
-/HER2
- but express CK5/6 [9] and in addition,
they show increased hypoxia and high tumor grade
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any medium, provided the original work is properly cited.[10,11]. Consequently, basal-like cancers have an aggres-
sive phenotype characterized by high cell proliferation
and poor clinical outcome but contrary to expectations,
we recently showed that these tumors do not always
show increased metastasis [12]. Most breast cancer asso-
ciated deaths are due to metastatic spread into distant
organs. This dissemination of tumor cells can occur
early in the cancer disease and often remains initially
undetected [13]. Cell migration is a prerequisite for
metastasis formation and we have shown previously that
several neurotransmitters induce migration of MDA-
MB-468 human breast carcinoma cells, with dopamine
and norepinephrine having the strongest effects [14]. In
these cells, the enhanced migratory activity in response
to norepinephrine is based on the activation of the
motor protein non-muscle myosin II [15], and is accom-
panied by changes in gene expression towards a metas-
tatogenic phenotype [16]. Similarly, chemokines and
cytokines are released in the tumor environment by the
tumor cells themselves as well as leukocytes, fibroblasts
and other cells of the tumor stroma. Therefore, tumors
are often compared with non-healing wounds, and these
inflammatory mediators are supposed to support tumor
progression with regard to metastasis formation [17,18].
Previous studies have shown that hypoxia can induce
basal-like and epithelial-to-mesenchymal transition
(EMT) properties in breast cancer [19]. In the current
study, we hypothesised that hypoxia induces cell migra-
tion in breast cancer and that this is achieved through
the involvement of inflammatory cell mediators. We
investigated the migratory activity of luminal (MCF-7),
post-EMT (MDA-MB-231, MDA-MB-435S), and basal-
like (MDA-MB-468) human breast carcinoma cell lines
under normal and oxygen-deprived conditions and the
secretion of inflammatory cytokines and chemokines.
Methods
Breast cancer cell lines
We used four human breast carcinoma cell lines for all
experiments, selected for being representative of the
luminal-like (oestrogen receptor (ER) positive) and
basal-like molecular classes described in breast cancer
gene expression studies [20-25] (Table 1). MCF-7 is a
well characterised ER-positive (luminal-like) cell line.
MDA-MB-231 and MDA-MB-435S share basal-like
properties and are classified as post-epithelial-mesenchy-
mal transition (post-EMT) cells due to vimentin positiv-
ity [26,27]. MDA-MB-468 is a basal-like cell line
expressing cytokeratin (CK) 5/6 [28,29].
The cell line MCF-7 was derived from the German
Collection of Microorganisms and Cell Cultures (DSMZ,
Braunschweig, Germany), the cell lines MDA-MB-231,
MDA-MB-435S and MDA-MB-468 were derived from
the American Type Culture Collection (ATCC, Mana-
ssas, VA). The three MDA-MB cell lines were cultured
in DMEM medium (PAA, Pasching, Austria) containing
10% heat-inactivated fetal calf serum (PAA), and the
MCF-7 cells were cultured in RPMI medium (PAA)
containing 10% heat-inactivated fetal calf serum and 1%
penicillin/streptomycin solution (50 U/ml and 50 μg/ml,
r e s p e c t i v e l y ;G I B C O ,E g g e n s t e i n - L e o p o l d s h a f e n ,G e r -
many), in addition supplemented with non-essential
amino acids (PAA), 1 mM sodium pyruvate (Biochrom
AG, Berlin, Germany) and 10 μg/ml insulin (Sigma-
Aldrich, Taufkirchen, Germany). All cultures were kept
at 37°C in a humidified atmosphere containing 5% CO2.
Hypoxia was induced by a stepwise oxygen-deprivation
in hypoxia-chambers (Billups-Rothenberg, Del Mar,
CA). The cells were kept for two days at 10% O2,f o r
one day at 5% O2,a n df o ro n ed a ya t1 %O 2 with con-
stantly 5% CO2 and the remainder being N2.I ti sw o r t h
to note that there is currently no consistent standard
protocol for the in vitro induction of hypoxia in tumor
cells.
Isolation of neutrophil granulocytes
Human neutrophil granulocytes (NG) were isolated
from peripheral blood of voluntary healthy donors by a
two-step protocol as described previously [15].
Informed consent was obtained from all donors
according to the Declarationo fH e l s i n k i .T h eo r i g i no f
the blood was blinded and made anonymous according
to ethic requirements. The heparinized blood was
diluted with PBS (1:1.7). Neutrophil granulocytes
together with erythrocytes were separated from the
peripheral blood mononuclear cell fraction by density
gradient centrifugation on lymphocyte separation med-
ium (LSM 1077; PAA, Pasching, Austria). Subse-
quently, NG were isolated by mixing platelet-depleted
serum from the same blood donor, diluted 1:1.3 with a
high molecular weight dextran solution (Macrodex;
Fresenius, Bad Homburg, Germany) containing 0.01 M
EDTA. After 3 hours, the supernatant containing gran-
ulocytes was isolated and any remaining erythrocytes
were removed by hypotonic lysis with 0.3% sodium
chloride on ice. NG were used for experiments imme-
diately after isolation.
Table 1 Characterisation of the investigated breast
cancer cell lines
Cell line ER PGR HER-2 EGFR CK5/6 Vimentin
MDA-
MB-231
negative negative normal positive negative positive
MDA-
MB-435S
negative negative amplified negative negative positive
MDA-
MB468
negative negative normal positive positive negative
MCF-7 positive positive normal negative negative negative
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The three-dimensional collagen-based migration assay
was performed as described previously [15]. In brief, 8 ×
10
4 tumor cells or 2.5 × 10
5 NG were resuspended in
50 μl of normal culture medium without any supple-
ments, or in culture medium conditioned by either nor-
moxic or hypoxic tumor cells. Conditioned medium was
prepared as follows: 500,000 cells of each cell line were
seeded in 4 ml full culture medium and cultured under
normoxic or hypoxic conditions as described above.
After three days (at the time when the oxygen content
was reduced from five to one percent concerning the
hypoxic cells) the regular culture media was removed
and replaced by 1 ml of the media without supplements.
After incubation for 24 hours at one percent oxygen,
remaining cells were removed from the media by centri-
fugation and these conditioned media were immediately
used for the experiments. Normoxic and hypoxic cells
were used for the migration experiments immediately
after completing the oxygen deprivation protocol
described in the “Breast cancer cell lines” paragraph.
The cell suspensions were mixed with 100 μl of a buf-
fered collagen solution (pH 7.4), containing 1.67 mg/ml
bovine collagen type I (Invitrogen, Cohesion Technolo-
gies, Palo Alto, CA). This mixture was filled into self-
constructed migration chambers, which consisted of a
microscopic glass slide, wax walls on three sides, and a
cover slip on top. After polymerization of the collagen
at 37°C in a humidified 5% CO2 atmosphere, the
remaining chamber volumes were filled with the same
media that were used for the cell suspensions, and the
chambers were sealed on the fourth side with wax. The
migration of the cells was recorded by time-lapse video-
microscopy for 1 hour (NG) or for 15 hours (tumor
cells) at 37°C. The paths of 30 randomly selected cells
were digitized by computer-assisted cell tracking and
the part of moving cells was calculated for each time
interval, one minute for NG or 15 minute for tumor
cells. Inhibition of the non-muscle myosin II activity
was achieved using the specific pharmacological inhibi-
tor blebbistatin in all cell lines. Statistically significant
changes were calculated from the mean migratory activ-
ities in the steady state phase using the unpaired and
undirected Student’s t test. A P value lower than 0.05
was considered statistically significant; the P value is
provided wherever statistical significance was reached.
Proliferation assay
The proliferation of tumor cells under normoxic and
hypoxic conditions was measured by bioreduction of the
tretrazolium salt XTT to a formazan derivative with
phenazine methosulphate (PMS) as an intermediate
electron acceptor [30]. For each condition, ten samples
of 5,000 cells in 300 μl medium were seeded per well in
a 96-well plate and grown for four days under normoxic
conditions or according to the hypoxia protocol
described above. After washing with PBS, the cells were
incubated for 4 hours at 37°C in 250 μl culture medium
without phenol red (PAA), and 50 μl XTT/PMS-solu-
tion (freshly prepared mixture of 5 ml XTT (1 mg/ml)
and 25 μl PMS (5 mM)). The XTT-formazan derivative
was measured at 450 nm using a microplate reader (Bio-
Tek Instruments, Bad Friedrichshall, Germany).
Flow cytometric analysis of cytokine and chemokine
release
Flow-cytometry analysis of released signal substances
was performed using a fluorescent immunoassay based
FlowCytomix kit (Bender MedSystems, Vienna, Austria)
according to the manufacturer’s protocol. Levels of the
following chemokines and cytokines were assessed: G-
CSF (granulocyte-colony stimulating factor), IFN-a and
-g (interferon-a and -g), interleukin-1a,- 1 b, -2, -4, -5,
-6 and -8, IP-10 (IFN-g inducible protein-10), MCP-1
(monocyte chemoattractant protein), MIG (monokine
induced by IFN-g), MIP-1a and -1b (macrophage
inflammatory protein-1a and -1b), NGF (nerve growth
factor), RANTES (regulated on activation, normal T-cell
expressed and secreted), and TNF-a (tumor necrosis
factor -a).
One million cells of each cell line were incubated in 2
ml culture medium as described in the “Breast cancer
cell lines” chapter either under normoxic or hypoxic
conditions. After completing three days of oxygen depri-
vation, or the same time under normal culture condi-
tions, the regular culture media was removed and
replaced by 1 ml of the media without supplements.
After further 24 hour incubation either at one percent
oxygen or normoxia, the cell culture supernantants were
collected and remaining cells were removed by centrifu-
gation. These supernatants were directly applied to the
above described FlowCytomix kit for the investigation of
the indicated chemokines and cytokines.
PCR analysis
The expression of HIF-1a and of its regulated down-
stream target gene carbonic anhydrase IX (CA IX) was
analysed by PCR. Total RNA was isolated from all
tumor cell lines using the NucleoSpin RNA II kit
(Machery&Nagel, Düren, Germany). An equal amount
of RNA of each sample (2 μg) was transcribed into
cDNA using a First Strand cDNA Synthesis Kit (Fer-
mentas, St. Leon-Rot, Germany). The resulting cDNA
was amplified in 40 cycles. CA IX specific primer
sequences were: forward: 5’-GCA GGA GGA TTC CCC
CTT G-3’;r e v e r s e :5 ’-GGA GCC TCA ACA GTA GGT
AGA T -3’ (annealing temperature 56.1°C; resulting in a
228 base pair product), and HIF-1a specific primer
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AAA AAG-3’; reverse: 5’- C C TT A TC A AG A TG C G
AAC TCA CA-3’ (annealing temperature 56.65°C;
resulting in a 154 base pair product). PCR products
were then subjected to gel electrophoresis on a 1.7%
agarose gel (Roth, Karlsruhe, Germany) and ethidium
bromide staining. A 100 base pair DNA Ladder (Fer-
mentas) was used to control the correct size of the PCR
products. Staining intensities were quantified using the
ImageJ software (NHI, Bethesda, MD).
Results
Migratory activity in response to oxygen deprivation
All of the investigated tumor cells developed sponta-
neous migratory activity after incorporation within a
three-dimensional collagen matrix (Figure 1). This
migratory activity increased when the cells were incu-
bated under hypoxic conditions. The migratory activity
of MDA-MB-231 cells increased from 44.9 ± 18.0 to
69.4 ± 0.5% locomoting cells, the migratory activity of
MDA-MB-435S cells increased from 35.5 ± 9.2 to 59.2
± 12.2% locomoting cells, the migratory activity of
MDA-MB-468 cells increased from 50.4 ± 10.8 to 64.8
± 9.0% locomoting cells, and the migratory activity of
MCF-7 cells increased from 43.1 ± 8.5 to 56.4 ± 6.9%
locomoting cells. Although these changes were strong
and self-evident, they did not reach statistical signifi-
cance due to the high standard deviations, whereas the
most obvious increases in MDA-MB-231 and MDA-
MB-435S cells were close to the significance level (P =
0.078 and P = 0.055, respectively). However, the migra-
tory activity of both normoxic and hypoxic cells was sig-
nificantly down-regulated to the same level by inhibition
of the non-muscle myosin II activity with the specific
pharmacological inhibitor blebbistatin in all cell lines
(Figure 1): Down-regulation in normoxic MDA-MB-231
cells to 21.6 ± 3.5% locomoting cells (P = 0.048), and
hypoxic MDA-MB-231 cells to 25.8 ± 6.8% locomoting
cells (P = 0.003); down-regulation in normoxic MDA-
MB-435S cells to 15.4 ± 6.2% locomoting cells (P =
0.034), and hypoxic MDA-MB-435S cells to 22.1 ± 2.5%
locomoting cells (P = 0.027); down-regulation in nor-
moxic MDA-MB-468 cells to 21.1 ± 3.0% locomoting
cells (P = 0.003), and hypoxic MDA-MB-468 cells to
25.0 ± 10.6% locomoting cells (P = 0.020); down-regula-
tion in normoxic MCF-7 cells to 16.2 ± 5.2% locomoting
cells (P = 0.003), and hypoxic MCF-7 cells to 20.1 ±
13.4% locomoting cells (P = 0.027).
Induction of tumor cell migration by conditioned medium
Both normoxic and hypoxic cell culture supernatants
strongly stimulated the migratory activity of their
respective cell line, with the hypoxic supernatant having
Figure 1 Migratory activity of tumor cells lines in response to
hypoxia. The graphs show mean values of three independent
experiments (90 cells were analyzed per sample). Blebbistatin
(Blebb) was used at a concentration of 100 μM.
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natant were statistically significant for MDA-MB-231
(P = 0.033) and MDA-MB-435S cells (P <0 . 0 0 1 ) .
Normoxic and hypoxic cell culture supernatants, respec-
tively, stimulated the migratory activity of MDA-MB-
231 cells to 66.1 ± 3.3 and 78.5 ± 0.6% locomoting cells,
of MDA-MB-435S cells to 35.2 ± 0.4 and 50.4 ± 3.0%
locomoting cells, of MDA-MB-468 cells to 50.3 ± 1.6
and 58.1 ± 12.6% locomoting cells, and of MCF-7 cells
to 59.8 ± 9.4 and 71.8 ± 4.5% locomoting cells.
Release of inflammatory mediators: cytokines and
chemokines
Expression levels of cytokines and chemokines released
from the cell lines under normoxic and hypoxic condi-
tions are shown in Figure 3 (supplemented by Table 2).
Generally, the non-luminal cell lines differed significantly
to the luminal MCF7 cell line in expressing IL-8 chemo-
kine. The post-EMT cell line MDA-MB-231 differed to
the other post-EMT, basal and luminal cell lines in being
the only cancer cell line showing IL-6 and G-CSF cyto-
kine and IP-10 chemokine expression. The post-EMT
MDA-MB-435 and basal cell line MDA-MB-468 were
similar in expressing MCP-1. Only the MCF7 cell line
showed G-CSF expression. All cells expressed low levels
of RANTES and its expression was increased in hypoxic
conditions for the MCF7 cell line. Levels of cytokine and
chemokine were different between cell lines cultured in
hypoxic and normoxic conditions when expressed.
Cell proliferation and hypoxia-associated gene expression
induced by hypoxic conditions
In contrast to the migratory activity, tumor cell prolif-
eration was not markedly influenced by oxygen depriva-
tion, as shown by an XTT assay (Figure 4A). In
comparison to normal oxygen conditions, hypoxic
MDA-MB-231 cells showed a small reduction in prolif-
eration to 91.9 ± 10.5%, MDA-MB-435S cells showed
increased proliferation to 107.5 ± 10.5%, as did MDA-
MB-468 cells to 105.0 ± 17.2%, and MCF-7 cells to
106.5 ± 11.9% (Figure 4A). None of these changes was
statistically significant. These results have confirmatory
character with regard to the fact that the amount of
released cytokines and chemokines do not vary as a
result of distinct proliferation activities.
Gene expression changes were seen for CA IX and
HIF-1a in all the cell lines investigated (Figure 4B).
RNA levels for CA IX and HIF-1a generally were upre-
gulated by oxygen deprivation. This increase of CA IX
expression delivers proof that the herein used protocol
for oxygen deprivation causes the well described meta-
bolic switch in the breast cancer cell lines.
Figure 2 Influence of cell culture supernatants on the
migratory activity of the tumor cell lines. The graphs show
mean values of three independent experiments (90 cells were
analyzed per sample). SN = supernatant.
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Figure 3 Release of cytokines and chemokines under normoxic and hypoxic cell culture conditions. Concentrations are given in ng per
ml culture medium, which accounts for 500,000 cells that were initially seeded. Please note, that the scale of the ordinate differs between the
cell lines
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T h ea b i l i t yo fc o n d i t i o n e dm e d i u m( C M )t oi n d u c e
migratory activity on NGs was investigated (Figure 5).
Conditioned medium from the cell lines that released
high amounts of chemokines i.e.M D A - M B - 2 3 1a n d
MDA-MB-435S cells, significantly stimulated the migra-
tory activity of NGs regardless of whether hypoxic or
normoxic culture conditions were used (Figure 5). CM
from both normoxic and hypoxic MDA-MB-231 cells
increased migratory activity from 17.1 ± 14.5% to 75.2 ±
18.0% (P = 0.002) and to 73.4 ± 18.3% (P =0 . 0 0 3 ) ,
respectively. CM from normoxic and hypoxic MDA-MB-
435S cells increased the migratory activity from 17.1 ±
14.5% to 73.7 ± 17.5% (P =0 . 0 0 2 )a n dt o7 3 . 8±1 6 . 4 %( P
= 0.002), respectively. In contrast, CM from MDA-MB-
468 cells had no influence on the migratory activity of
NGs, while MCF-7 CM from cells grown under hypoxic
conditions only weakly stimulated the migratory activity
from 17.1 ± 14.5% to 22.8 ± 15.6% locomoting cells.
The only chemokine that was released by all the non-
luminal breast cancer lines, (MDA-MB-231, MDA-MB-
435S and MDA 468) was interleukin-8, but blockade of
the relevant receptors CXCR1 and CXCR2 with appro-
priate antibodies only slightly reduced the migratory
activity of NG suggesting that other mediators might be
involved in their activation (data not shown).
Discussion
Hypoxia is associated with some forms of high grade
breast tumors including basal-like cancers and is
associated with poor prognosis [10,11,31,32]. The rea-
son for tumor hypoxia is generally believed to result
from tumor cell growth outstripping the rate of angio-
genesis [2,3] and consequently, cancer cells react by
upregulation of HIF-1a gene and its downstream tar-
get genes, including CA IX. One has to keep in mind
that experimental normoxic conditions with 21 per-
cent oxygen in cell culture are likely to be higher than
in vivo oxygen tensions. Although much effort has
been made to detect hypoxic regions within tumors, e.
g. by positron-emission tomography [33,34], absolute
oxygen tensions are difficult to measure. In glial-
derived tumors, measurements of 10 to 0.5 precent
oxygen were defined as moderate hypoxia, whereas
oxygen tensions at 0.1 percent were defined as severe
hypoxia [35]. Therefore, oxygen deprivation in vitro
can only provide results in a comparative manner
between cells incubated at different oxygen concentra-
tions, regardless which of the widely varying oxygen
deprivation protocols is used.
O u rr e s u l t sp r o v i d ee v i d e n c et h a th y p o x i ag e n e r a l l y
increases the migratory activity of breast carcinoma cells
but does not appear to influence tumour cell prolifera-
tion. This might explain the observation that anti-angio-
genic therapeutic treatment can lead to an enhanced
metastasis formation [6,8]. Thus, such treatment should
be accompanied by anti-metastatic strategies that inhibit
tumor cell migration and metastasis formation. A better
understanding of the mechanism by which the migratory
activity is induced could lead to targeted therapy.
Table 2 Release of substances by the tumor cell lines
Chemokine or
cytokine
MDA-231
normoxic
MDA-231
hypoxic
MDA-435
normoxic
MDA-435
hypoxic
MDA-468
normoxic
MDA-468
hypoxic
MCF-7
normoxic
MCF-7
hypoxic
RANTES 6.04 3.37 13.30 5.69 0.94 0.41 2.08 3.10
MCP-1 47.58 35.71 4.18 3.49
MIG
MIP-1alpha 0.17 0.27 0.11 0.29
MIP-1beta
IL-8 22.14 22.41 31.63 24.66 11.57 11.01
IP-10 12.90 8.90 0.19 0.07
IL-1alpha 0.05 0.30
IL-1beta 0.38 1.02 0.36 0.12 0.33
IL-2 0.83 0.65 0.75 0.83
IL-4 0.41 0.55 0.38 0.53 0.47
IL-5
IL-6 63.32 57.23 0.62 0.49
IFN-alpha
IFN-gamma 0.14 0.25
TNF-alpha 0.39 0.66
NGF 14.42
G-CSF 13.98 12.17
Note: This table supplements Figure 3 by providing the actual values (ng/ml).
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noma cells stimulate their own migratory activity by the
release of interleukin-8 even under normal (non-hypoxic)
conditions in an autocrine fashion [36]. Furthermore,
several classes of axon guidance molecules have been
reported to act in an autocrine fashion in cancer cells,
too, inducing invasion and metastasis development [37].
Thus, autocrine activation of tumor cell migration seems
to be a frequent phenomenon and is supported by the
results in the current study where, even under normoxic
conditions, tumor cells release inflammatory mediators
that stimulate their own migratory activity.
CA IX
HIF-1
+54% +109% +333% +11% +35% +25% +21% +7%
MDA-MB-231 MDA-MB-435S MDA-MB-468 MCF-7
A
B
n     h      n      h     n     h      n      h     n      h    n      h                         n      h       n      h
Figure 4 Growth and HIF-1a/CA IX expression of the tumor cell lines in response to hypoxia. (A) The growth of tumor cells under
hypoxic conditions was compared to the growth under normal (normoxic) cell culture conditions. The graph shows mean values and standard
deviations of three independent experiments. (B) The expression of HIF-1a and its target gene CA IX in the tumor cells under normoxic (n) and
hypoxic (h) conditions was analysed by PCR. Numbers show the percent increase of staining intensities in hypoxic cells in comparison to
normoxic cells. The shown blot holds true for three independently performed analyses with similar results.
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cytokine and chemokine mediators change under
hypoxic conditions to strongly enhance migratory activ-
ity. However, there is no common signal substance
upregulated in all investigated cancer cell lines, which
leads to the conclusion that the cytokine or chemokine
responsible for the increase in the migratory activity
either differs between the various cell lines, or is not
among the herein investigated signal substances. There-
fore, further studies are needed to characterize this
ligand in each cell line, e.g. by knockdown experiments
or receptor-blocking antibodies. In the current study, we
have shown that the non-luminal breast cancer cell lines
including MDA-231, MDA-435 and MDA-468 are all
characterised by increased IL-8 production compared to
the luminal MCF7 cell line. Previous studies have shown
that IL-8 is produced in response to cell stress, includ-
ing hypoxia [38], and can induce increased cell migra-
tion, proliferation, angiogenesis and neutrophil
recruitment [39]. Moreover, IL-8 increases metastasis
and can cause resistance to chemotherapy [39]. Intrigu-
ingly, our data suggests that IL-8 production could be
an intrinsic property of the non-luminal cancer pheno-
type because the post-EMT and basal cell lines investi-
g a t e dh e r eb o t hs h o w e dI L - 8p r o d u c t i o n ,w h e r e a st h e
luminal cell lines did not. Moreover, we found little or
no difference in IL-8 production in response to hypoxia
among the non-luminal cancer cell lines. Our data may
confirm an involvement of IL-8 in breast cancer cell
migration, and support previous studies concerning the
role of IL-8 in tumour cell migration [36]. In vitro stu-
dies have recently shown that microRNA (miRNA) 17/
20 can inhibit migration of post-EMT MDA-MB-231
breast cancer cells by repressing IL-8 [40]. However,
these data do not explain the higher migratory activity
under hypoxia as compared to normoxia, since IL-8
release does not increase in response to oxygen depriva-
tion. Besides a blockade of the responsible receptors,
once the ligands are identified, other possible mechan-
isms for attenuating cancer cell migration involve inhibi-
tion of the cytoskeletal non-muscle myosin II, which is a
key mediator of locomotory force generation in the
migration of carcinoma cells and leukocytes [15]. Here
we provided evidence of the functionality of this path-
way by the blockade of non-muscle myosin II in tumor
cells using the specific inhibitor blebbistatin, which
completely abolished migration in cancer cell lines and
in neutrophil granulocytes treated with conditioned
medium.
Our observation that hypoxic cells release inflamma-
tory mediators capable of neutrophil recruitment could
explain why some basal-like cancers are associated with
Figure 5 Response of neutrophil granulocytes to cell culture
media conditioned by tumor cells under normoxic (norm) or
hypoxic (hyp) conditions. The graphs show mean values of four
independent experiments (120 cells were analyzed per sample). SN
= supernatant.
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Page 9 of 12an extensive inflammatory infiltrate [41,42]. Together
with macrophages, neutrophil granulocytes can make up
to 50 percent of the tumor mass [43]. Conflicting reports
have shown an association between the presence of
inflammatory cells, principally CD8
+ Tl y m p h o c y t e s ,a n da
role in metastasis formation and clinical outcome [44].
Basal-like medullary cancers are associated with a mixed
inflammatory cell pattern and this is generally thought to
be due to a host response to focal necrosis that is com-
monly seen with this tumor type. But, our data suggest
that tumour cells might take an active role in recruiting
inflammatory cells through production of pro-inflamma-
tory mediators. We showed that not all basal cells have
this capability because only conditioned medium from
MDA-MB-231 and MDA-MB-435S cells significantly
increased the migratory activity of NGs, and that this
property is intrinsic, irrespective of hypoxic conditions.
Although there seem to be strong similarities between
MDA-MB-231 and MDA-MB-435S cells, it is necessary to
mention that the provenance of MDA-MB-435S is ques-
tionable because it may have evolved from a melanoma
cell line [45,46]. More recently, MDA-MB-435 cells have
been described as breast cancer cells expressing melanocy-
tic differentiation markers [47]. In contrast to the other
basal-like cell lines, conditioned medium released by
MDA-MB-468 did not induce neutrophil migratory activ-
ity, and medium from hypoxic MCF-7 cells only weakly
stimulated neutrophil migratory activity.
Interestingly, although hypoxia led to an increase of
HIF1-a and CA IX RNA expression in all the cell lines,
our study did not show significant differences in the
RNA levels of HIF-1a or CA IX, or a correlation with
migratory activity, irrespective of phenotype. A possible
explanation for this is due to the in vitro cancer cell
model used in our study with its absence of fibroblasts.
There is increasing evidence showing tumor-stromal
interaction is important in influencing tumor aggressive-
ness. Previous studies have shown that conditioned
medium from tumor-derived fibroblasts can promote
basal-like properties including EMT [48]. In addition,
although basal-like breast cancers have been reported to
show a generally worse prognosis than luminal-like can-
cers [49], the tumor biological grade is of fundamental
importance in determining clinical outcome. It has been
proposed that hypoxia might induce EMT by an upregu-
lation of TWIST and other EMT-regulators [50,51],
contributing to basal-like properties. Our results show,
that the release of signal substances by tumor cells does
not only influence the tumor-stormal interaction, as
described by other groups [48], but has direct autocrine
effects, too, painting an even more complex picture on
how hypoxia promotes tumor progression.
Conclusions
The migratory activity of the luminal and non-luminal
breast tumour cell lines investigated in this study
showed increased migration, mediated in an autocrine
fashion, under oxygen deprivation. We found differential
patterns of cytokines and chemokines between luminal
and non-luminal breast cancer cell lines and changes for
some mediators when the cell lines were subjected to
hypoxia. Importantly, post-EMT and basal cell lines
were characterised by IL-8 production whereas it was
absent in the luminal-type MCF7 cell line. Targeting of
IL-8 could present a therapeutic strategy for reducing
tumour metastasis in breast cancer.
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